Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall ...

We list the best Gantt chart software, to make it simple and easy to better visualize and manage progress when dealing with larges projects. Gantt chart software can be a powerful weapon in a ...

We list the best free Gantt chart software, to make it simple and easy to follow the progress of project management schedules, without a paid-for subscription. A Gantt chart is a very important ...

The below chart from UCSF Benioff Children’s Hospital outlines the normal range of beats per minute for resting heart rate, based on age. Target heart rate refers to a range of heart beats per ...

Alsfouk et al. employed a computer-assisted design strategy to identify potential CDK9 and CYP3A4 inhibitors by using a predictive QSAR model and in silico synthesis. Molecular docking studies ...

The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China ...

The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to ...

SELLAS focuses on developing innovative cancer therapies, including their lead candidate GPS, which targets the WT1 protein, and SLS009, a small molecule CDK9 inhibitor. SELLAS Life Sciences has ...

The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared ...